Allergan, Inc. (NYSE:AGN)
| CAPS Rating |
|
|---|---|
| Open | $86.96 |
| Previous Close | $87.38 |
| Daily Range | $86.56 - $87.34 |
| 52-Week Range | $68.03 - $90.00 |
| Market Cap | $26.56B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | 0.20 (0.30%) |
| Volume | 1,375,371 |
| Average Daily Volume | 0 |
AGN
VS S&P 500 (SPY)
How do you think AGN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
AGN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
AGN News and Commentary
- Allergan Terminates Sales of Lap-Band – Blogs @ The Motley Fool
- Golf Clap for Allergan – The Motley Fool
- Earnings Beat for Allergan - Analyst Blog – NASDAQ
- UPDATE: Allergan 4Q Net Rises 6.3% On Eye Care Sales – SmartMoney
- CORRECT: Allergan 4Q Net Rose 6.3%, Margins Improve; R&D Costs Higher – SmartMoney
- Botox Maker Erases Doctor Payment Records – Minyanville
- Opening View: DJIA Flat Ahead of Jobless Claims, Bernanke Speech – NASDAQ
- Earnings Preview: Allergan - Analyst Blog – NASDAQ
- Allergan Looks to Benefit from Botox Demand, Business Mix – Minyanville
- Solta's LIPOSONIX Reaches the U.S. - Analyst Blog – NASDAQ
- FDA Warns Calif Surgery Centers About Misleading Lap-Band Ads – SmartMoney
- Are Allergan's Numbers Better Than They Look? – The Motley Fool
- Why the Street Should Expect Big Things From Merck – The Motley Fool
- Is Merck Working Hard Enough for You? – The Motley Fool
- Medical Devices: Venture Capitalists Lobby to Change FDA Approval Process – NASDAQ
- Why the Street Should Expect Big Things from Bristol-Myers Squibb – The Motley Fool
- Medical Devices: Venture Capitalists Lobby to Change FDA Approval Process – The Motley Fool
- How Healthy Is Opko Health's Growth? – The Motley Fool
- AGN 3Q Earnings Alert: Thomson Reuters 90 Cents – SmartMoney
- Don't Get Too Worked Up Over Allergan's Earnings – The Motley Fool
RSS Headlines
Fool UK
